年龄相关性黄斑变性干预系统评价的质量评价:一项系统评价
该研究系统检索Ovid MEDLINE、Embase和Cochrane Library(建库至2017年3月),纳入71篇AMD干预系统评价,用AMSTAR工具评估方法学质量。平均AMSTAR得分为5.8/11.0,随时间无显著改善;Cochrane系统评价质量高于其他期刊。
要点
- AMD干预系统评价方法学质量变异大,平均AMSTAR得分5.8/11.0。
- Cochrane系统评价平均AMSTAR得分9.9,高于其他期刊的4.7(P < .001)。
- 仅31%文章提及先验设计,23%报告利益冲突, adherence较差。
核心结论
- AMD领域系统评价的实施存在差距,提高对PRISMA声明的采纳可能改善综述质量并促进可靠证据传播。
研究设计与样本
- 系统评价,遵循PRISMA声明,检索Ovid MEDLINE、Embase和Cochrane Library从建库至2017年3月,由两名评价者独立筛选,使用AMSTAR工具评估质量。
主要发现
- 共检索到983条引文,71篇(7.6%)符合纳入标准,首篇AMD干预系统评价发表于2003年,超过半数发表于2014年后。
- 平均(SD)AMSTAR得分为5.8(3.2)/11.0,随时间无显著改善(r = -0.03;95% CI,-0.26至0.21;P = .83)。
- Cochrane系统评价平均(SD)AMSTAR得分为9.9(1.2)(n=15),其他期刊为4.7(2.2)(n=56),P < .001。
- 提及先验设计的文章22篇(31%),报告综述和纳入研究利益冲突的文章16篇(23%)。
- 政府拨款和/或机构资助的综述质量一般高于企业资助或未报告资助来源的综述。
关键数值与推荐
- AMSTAR工具用于评估系统评价方法学质量,总分11.0。
- Cochrane系统评价平均AMSTAR得分9.9(1.2) vs 其他期刊4.7(2.2),P < .001。
- 先验设计提及率31%(22篇),利益冲突报告率23%(16篇)。
临床怎么用
- 临床医生在参考AMD干预系统评价时,需注意其方法学质量参差不齐,Cochrane系统评价质量较高。
- 建议关注系统评价是否提及先验设计及报告利益冲突,以判断证据可靠性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Age-related macular degeneration (AMD) is a leading cause of vision impairment. It is imperative that AMD care is timely, appropriate, and evidence-based. It is thus essential that AMD systematic reviews are robust; however, little is known about the quality of this literature. OBJECTIVES: To investigate the methodological quality of systematic reviews of AMD intervention studies, and to evaluate their use for guiding evidence-based care. EVIDENCE REVIEW: This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. All studies that self-identified as a systematic review in their title or abstract or were categorized as a systematic review from a medical subject heading and investigated the safety, efficacy and/or effectiveness of an AMD intervention were included. Comprehensive electronic searches were performed in Ovid MEDLINE, Embase, and the Cochrane Library from inception to March 2017. Two reviewers independently assessed titles and abstracts, then full-texts for eligibility. Quality was assessed using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool. Study characteristics (publication year, type of intervention, journal, citation rate, and funding source) were extracted. FINDINGS: Of 983 citations retrieved, 71 studies (7.6%) were deemed eligible. The first systematic review relating to an AMD intervention was published in 2003. More than half were published since 2014. Methodological quality was highly variable. The mean (SD) AMSTAR score was 5.8 (3.2) of 11.0, with no significant improvement over time (r = -0.03; 95% CI, -0.26 to 0.21; P = .83). Cochrane systematic reviews were overall of higher quality than reviews in other journals (mean [SD] AMSTAR score, 9.9 [1.2], n = 15 vs 4.7 [2.2], n = 56; P < .001). Overall, there was poor adherence to referring to an a priori design (22 articles [31%]) and reporting conflicts of interest in both the review and included studies (16 articles [23%]). Reviews funded by government grants and/or institutions were generally of higher quality than industry-sponsored reviews or where the funding source was not reported. CONCLUSIONS AND RELEVANCE: There are gaps in the conduct of systematic reviews in the field of AMD. Enhanced endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement by refereed journals may improve review quality and improve the dissemination of reliable evidence relating to AMD interventions to clinicians.
引用
- Downie LE, Makrai E, Bonggotgetsakul Y, et al. Appraising the Quality of Systematic Reviews for Age-Related Macular Degeneration Interventions: A Systematic Review. JAMA Ophthalmol. 2018. PMID: 29978192. doi:10.1001/jamaophthalmol.2018.2620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。